Krystal Biotech vs Ligand Pharmaceuticals
Krystal Biotech reported revenue of $389 million in fiscal 2025, 1.5 times Ligand Pharmaceuticals' $268 million in fiscal 2025. Krystal Biotech's revenue grew 33.9% in its latest year, and Ligand Pharmaceuticals' grew 60.4%. Krystal Biotech had an operating margin of 41.5%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was $189 million at Krystal Biotech and $49 million at Ligand Pharmaceuticals.
Side by side
| Krystal Biotech | Ligand Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $389M | $268M |
| Revenue growth | 33.9% | 60.4% |
| Revenue growth a year, last 5 years | — | 10.4% |
| Gross margin | — | — |
| Operating margin | 41.5% | 15.3% |
| Net margin | 52.6% | 46.4% |
| Free cash flow | $189M | $49M |
| Free cash flow margin | 48.5% | 18.2% |
| Return on capital | 43.6% | 4.9% |
| Net debt to EBITDA | −5.0x | −3.8x |
| Dividends and buybacks | $0M | $15M |
| Change in diluted share count | 0.7% | 11.0% |
| Last close | $313.66 | $308.30 |
| P/E at the last close | 39.3× | 32.8× |
| Insider trades, last 12 months | sold $105.3 million | sold $33.2 million |
| Piotroski F-score | 5 of 8 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Krystal BiotechLigand Pharmaceuticals
Operating margin
Percent of revenue
Krystal BiotechLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Krystal BiotechLigand Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Krystal Biotech and Ligand Pharmaceuticals pages.